Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab in Advanced Chronic Renal Disease in Japan
NCT04626505Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ziltivekimab in chronic kidney disease (CKD) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels at Week 12. Started Oct 2020; status: completed.
02
Drugs
ziltivekimab
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04626505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626505.